Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q1 FY27 results · Apr–Jun 2026
Torrent Pharmaceuticals reported revenue from operations of ₹4,921.00 crore (up 54.8% from Q1 FY26) and net profit of ₹566.00 crore (up 3.3% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4,921.00 | 3,178.00 | +54.8% | 4,197.00 | +17.3% |
| Other income | (12.00) | (37.00) | Loss narrowed | (17.00) | Loss narrowed |
| Total income | 4,909.00 | 3,141.00 | +56.3% | 4,180.00 | +17.4% |
| Profit before tax | 733.00 | 738.00 | −0.7% | 529.00 | +38.6% |
| Net profit for the period | 566.00 | 548.00 | +3.3% | 364.00 | +55.5% |
| EPS, basic (₹) | 14.87 | 16.19 | −8.2% | 11.51 | +29.2% |
| Net margin (%) | 11.5 | 17.2 | 8.7 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4,158.00 | 2,616.00 | +58.9% | 2,735.00 | +52.0% |
| Other income | (21.00) | (5.00) | Loss widened | 58.00 | Turned loss |
| Total income | 4,137.00 | 2,611.00 | +58.4% | 2,793.00 | +48.1% |
| Profit before tax | 663.00 | 742.00 | −10.6% | 592.00 | +12.0% |
| Net profit for the period | 492.00 | 551.00 | −10.7% | 467.00 | +5.4% |
| EPS, basic (₹) | 12.94 | 16.28 | −20.5% | 13.80 | −6.2% |
| Net margin (%) | 11.8 | 21.1 | 17.1 |
Consolidated
- Filed with BSE
- 30 Jul 2026, 17:34 IST
- Board meeting
- 30 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jul 2026, 17:34 IST
- Board meeting
- 30 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE